Cover Image
市場調查報告書

院內傳染病檢查的全球市場 2015-2019年

Global Hospital-acquired Disease Testing Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 336499
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
院內傳染病檢查的全球市場 2015-2019年 Global Hospital-acquired Disease Testing Market 2015-2019
出版日期: 2015年07月29日 內容資訊: 英文 92 Pages
簡介

全球院內傳染病檢查市場,預計從2014年到2019年的期間,以19.44%的年複合成長率成長。

本報告以全球院內傳染病檢查市場為主題,提供市場概要、市場發展推動因素、市場課題和那些的影響、各產品及地區市場現況與展望相關調查分析、主要國家市場分析、主要的供應商分析彙整。

第1章 摘要整理

第2章 簡稱集

第3章 調查範圍

  • 市場概要
  • 提供產品

第4章 市場調查手法

  • 市場調查的過程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第7章 院內感染疾病

  • 背景
    • HAI的症狀、預防、檢驗及診斷
  • HAI的發病率、盛行率
    • 已開發國家
    • 低-中所得國

第8章 市場區隔:各產品

  • 全球UTI檢驗市場
  • 全球SSI檢驗市場
  • 全球肺炎鏈球菌感染檢驗市場
  • 全球血流傳染病檢查市場
  • 全球 MRSA檢驗市場

第9章 地區區分

  • 南北美洲的染症檢驗市場
  • EMEA (歐洲、中東、非洲) 的染症檢驗市場
  • APAC (亞太地區) 的染症檢驗市場

第10章 購買標準

第11章 市場成長的促進要素

第12章 促進要素與其影響

第13章 市場課題

第14章 促進要素與課題的影響

第15章 市場趨勢

第16章 趨勢與其影響

第17章 業者情勢

  • 競爭情形
  • 市場佔有率分析
  • 其他有潛力的供應商

第18章 主要供應商分析

  • Abbott Laboratories
    • 主要資料
    • 營業內容說明
    • 產業區分
    • 產業策略
    • 收益:各產業分類
    • 收益比較
    • 收益:各區域區隔
    • 主要資訊
    • SWOT分析
  • Becton, Dickinson and Co.
  • bioMeriux
  • Roche Diagnostics

第19章 相關報告

圖表清單

目錄
Product Code: IRTNTR6608

About Hospital-acquired Diseases

Hospital-acquired diseases are also known as nosocomial infections that are acquired in hospitals and other healthcare facilities. These infections are classified only when a patient is admitted for reasons other than the infections and are caused by bacteria, fungi, parasites, or viruses. Most common types of hospital-acquired infections are SSIs, UTIs, bloodstream infections, pneumococcal infections, MRSA, and gastrointestinal illnesses. These infections appear between 48 hours and four days after a patient is admitted and are usually related to a treatment of procedure used to treat or diagnose the patient's initial illness or injury. Hospital-acquired diseases are preventable through adherence to strict guidelines and less usage of invasive equipment that must be followed by healthcare professionals while caring for the patient.

Technavio's analysts forecast the global hospital-acquired disease testing market to grow at a CAGR of 19.44% over the period 2014-2019.

Covered in this Report

In this report, Technavio covers the present scenario and the growth prospects of the global hospital-acquired disease testing market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of testing products used in the following hospital-acquired disease infections: SSIs, UTIs, bloodstream infections, pneumococcal infections, MRSA, and others.

Technavio's report, Global Hospital-acquired Disease Testing Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hospital-acquired disease testing market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Abbott Laboratories
  • Becton and Dickenson
  • bioMerieux
  • Roche Diagnostics
  • Other Prominent Vendor
  • Akers Biosciences
  • Alere
  • Beckman Coulter/Danaher
  • Cantel Medical
  • Cepheid
  • Diatherix Laboratories
  • Eiken Chemical
  • Enzo Biochem
  • Fujirebio/Innogenetics
  • Gen-Probe
  • Humor Diagnostica
  • Life Technologies
  • Meridian Bioscience
  • Nordion
  • QIAGEN

Market Driver

  • Rising Prevalence of HAIs
  • For a full, detailed list, view our report

Market Challenge

  • Lack of Healthcare Infrastructure
  • For a full, detailed list, view our report

Market Trend

  • Technological Advancements
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Hospital Acquired Infections/Hospital Acquired Diseases

  • 07.1. Background
    • 07.1.1. Symptoms, Prevention, Testing, and Diagnosis of HAIs
  • 07.2. Incidence and Prevalence of HAI
    • 07.2.1. Developed Nations
    • 07.2.2. Low and Middle-income Nations

08. Market Segmentation by Product

  • 08.1. Global UTI Testing Market
    • 08.1.1. Market Size and Forecast
  • 08.2. Global SSI Testing Market
    • 08.2.1. Market Size and Forecast
  • 08.3. Global Pneumococcal Infections Testing Market
    • 08.3.1. Market Size and Forecast
  • 08.4. Global Bloodstream Infections Testing Market
    • 08.4.1. Market Size and Forecast
  • 08.5. Global MRSA Testing Market
    • 08.5.1. Market Size and Forecast

09. Geographical Segmentation

  • 09.1. Hospital Acquired Disease Testing Market in Americas
    • 09.1.1. Market Size and Forecast
  • 09.2. Hospital Acquired Disease Testing Market in EMEA
    • 09.2.1. Market Size and Forecast
  • 09.3. Hospital Acquired Disease Testing Market in APAC
    • 09.3.1. Market Size and Forecast

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2014
    • 17.2.1. Abbott
    • 17.2.2. BD
    • 17.2.3. bioMerieux
    • 17.2.4. Roche Diagnostics
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. Abbott Laboratories
    • 18.1.1. Key Facts
    • 18.1.2. Business Description
    • 18.1.3. Business Segmentation
    • 18.1.4. Business Strategy
    • 18.1.5. Revenue by Business Segmentation
    • 18.1.6. Revenue Comparison 2011 and 2012
    • 18.1.7. Revenue by Geographical Segmentation
    • 18.1.8. Key Information
    • 18.1.9. SWOT Analysis
  • 18.2. Becton, Dickinson and Co.
    • 18.2.1. Key Facts
    • 18.2.2. Business Description
    • 18.2.3. Business Segmentation
    • 18.2.4. Revenue Segmentation by Business
    • 18.2.5. Segmental Revenue Comparison 2013 and 2012
    • 18.2.6. Revenue Segmentation by Geography
    • 18.2.7. Business Strategy
    • 18.2.8. Key Developments
    • 18.2.9. SWOT Analysis
  • 18.3. bioMeriux
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation by Revenue 2013
    • 18.3.4. Geographical Segmentation by Revenue 2013
    • 18.3.5. Business Strategy
    • 18.3.6. Recent Developments
    • 18.3.7. SWOT Analysis
  • 18.4. Roche Diagnostics
    • 18.4.1. Key Facts
    • 18.4.2. Business Overview
    • 18.4.3. Business Segmentation by Revenue 2014
    • 18.4.4. Business Segmentation by Revenue 2013 and 2014
    • 18.4.5. Geographical Segmentation by Revenue 2014
    • 18.4.6. Business Strategy
    • 18.4.7. Recent Developments
    • 18.4.8. SWOT Analysis

19. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Hospital Acquired Disease Testing Market 2014-2019 ($ millions)
  • Exhibit 3: Common HAIs in Acute Care Settings
  • Exhibit 4: Prevalence of HAI in Developed Nations
  • Exhibit 5: Prevalence of HAI in Low and Middle-Income Nations
  • Exhibit 6: Comparison of HAI in Developed and Low and Middle-income Nations
  • Exhibit 7: Hospital Acquired Infections in US (2011)
  • Exhibit 8: Estimated Treatment Cost and Mortality Associated with HAIs
  • Exhibit 9: Segmentation of Global Hospital Acquired Disease Testing Market by Product 2014
  • Exhibit 10: Global UTI Testing Market 2014-2019 ($ millions)
  • Exhibit 11: Global SSI Testing Market 2014-2019 ($ millions)
  • Exhibit 12: Global Pneumococcal Infections Testing Market 2014-2019 ($ millions)
  • Exhibit 13: Global Bloodstream Infections Testing Market 2014-2019 ($ millions)
  • Exhibit 14: Global MRSA Testing Market 2014-2019 ($ millions)
  • Exhibit 15: Global Hospital Acquired Disease Testing Market Segmentation Analysis 2014-2019
  • Exhibit 16: Segmentation of Global Hospital Acquired Disease Testing Market by Product Type 2014-2019
  • Exhibit 17: Global Hospital Acquired Disease Testing Market by Geographical Segmentation 2014
  • Exhibit 18: Hospital Acquired Disease Testing Market in Americas 2014-2019 ($ millions)
  • Exhibit 19: Hospital Acquired Disease Testing Market in EMEA 2014-2019 ($ millions)
  • Exhibit 20: Hospital Acquired Disease Testing Market in APAC 2014-2019 ($ millions)
  • Exhibit 21: Global Hospital Acquired Disease Testing Market Segmentation by Geography 2014-2019 ($ millions)
  • Exhibit 22: Global Hospital Acquired Disease Testing Market Segmentation by Geography (%)
  • Exhibit 23: Percentage of Elderly Aged above 65 in Different Regions 2012 and 2050
  • Exhibit 24: Estimated Percentage of Elderly Population 2012 and 2050
  • Exhibit 25: Immediate Control Measures for Management of HAIs
  • Exhibit 26: Direct Costs and Prevalence of HAI in Europe and US
  • Exhibit 27: Abbott Laboratories: Key Takeaways
  • Exhibit 28: BD: Key Takeaways
  • Exhibit 29: bioMerieux: Key Takeaways
  • Exhibit 30: Roche Diagnostics: Key Takeaways
  • Exhibit 31: Abbott Laboratories: Business Segmentation
  • Exhibit 32: Abbott Laboratories: Revenue by Business Segmentation 2012
  • Exhibit 33: Abbott Laboratories: Revenue by Business Segmentation 2011 and 2012 ($ millions)
  • Exhibit 34: Abbott Laboratories: Revenue by Geographical Segmentation 2012
  • Exhibit 35: Becton, Dickinson and Co.: Product Categorization
  • Exhibit 36: Becton, Dickinson and Co.: Revenue Segmentation 2013
  • Exhibit 37: Becton, Dickinson and Co.: Revenue Comparison ($ millions)
  • Exhibit 38: Becton, Dickinson and Co.: Geographical Segmentation 2013
  • Exhibit 39: bioMeriux: Business Segmentation by Revenue 2013
  • Exhibit 40: bioMeriux: Geographical Segmentation by Revenue 2013
  • Exhibit 41: Roche Diagnostics: Business Segmentation by Revenue 2014
  • Exhibit 42: Roche Diagnostics: Business Segmentation by Revenue 2013 and 2014 ($ billion)
  • Exhibit 43: Roche Diagnostics: Geographical Segmentation by Revenue 2014
Back to Top